CANON ADDS EOS R50 AND EOS R8 TO THE GROWING EOS R 8-02-2023, 11:21

Nexstim Plc: Approved delisting application regarding the 9-02-2023, 23:17

Io Therapeutics, Inc., presented data from studies of IRX4204, the company’s phase II clinical development stage, highly selective third generation RXR nuclear receptor agonist compound, supporting its potential use for prevention and treatment of normal 10-07-2024, 07:00